Identification of Serum CMTM2 as a Potential Biomarker for HBV-Related Disorders

Abstract EN

Substantial advance supports that CMTM2 serve as an important performer in physiological and pathological processes.

However, very little is clear about the relationship between CMTM2 and HBV-related disorders.

Here, for the first time, we explore that whether or not serum CMTM2 is involved in HBV-related diseases.

We found that CMTM2 values were significantly lower in patients compared to healthy control (p <0.001), using ELISA assay.

Furthermore, serum CMTM2 levels were negatively correlated with HBV DNA levels in CHB patients but not correlated with the serum levels of ALT and AST.

Serum CMTM2 concentrations were not correlated with the serum levels of ALT, AST and HBV DNA load in HBLC and HCC patients.

In addition, analysis of the ROC curve indicated that CMTM2 levels were significantly associated with the diagnostic value of HBV-related disorders.

Finally, downregulation of CMTM2 was observed in HBV-infected cell model.

CMTM2 degradation could be attributed to HBx-activated Lys48 (K48)-linked polyubiquitination, which was abolished by treatment with the proteasome inhibitor MG132.

HBV infection suppresses CMTM2 expression by activating ubiquitin-proteasome system.

Serum CMTM2 levels can be adopted as an effective indicator of the pathogenesis of HBV-related disorders.